2024
Comparative Effectiveness of SBRT
Shen J, Sritharan D, Yu J, Aneja S. Comparative Effectiveness of SBRT. 2024, 455-467. DOI: 10.1007/978-3-031-67743-4_33.Peer-Reviewed Original ResearchStereotactic body radiation therapyEffect of stereotactic body radiation therapyAlternative to other treatment modalitiesStereotactic body radiation therapy treatmentLong-term follow-up of patientsFollow-up of patientsLong-term follow-upTreatment of brainOligometastatic diseaseRadiation therapyTreatment of cancerRetrospective seriesTreatment modalitiesRenal cancerCost-effectiveness studiesDatabase analysisCancerTreatmentProstateTherapyInappropriate Denials for Radiation Therapy in Medicare Advantage Plans
Pasetsky J, Bhatt K, Kachnic L, Yu J, Horowitz D. Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans. International Journal Of Radiation Oncology • Biology • Physics 2024, 121: 871-874. PMID: 39551102, DOI: 10.1016/j.ijrobp.2024.11.063.Peer-Reviewed Original ResearchConceptsIntensity-modulated RTRadiation therapyStereotactic body radiation therapyHealth servicesMedicare Advantage plansMedicare-eligible patientsChi-square testRadiation oncologistsProstate cancerTreatment modalitiesBreast cancerCancer treatmentTherapyCancerRT servicesPolicy changesMedicaid Services websiteCoverage guidelinesDenial ratesMedical specialtiesCenters for Medicare & Medicaid Services websiteTreatmentDenialBrachytherapyProstateRadiation Therapy for the Treatment of Osteoarthritis
Yu J, Grew D, Spraker M, Beckta J, Shah C, Brower J. Radiation Therapy for the Treatment of Osteoarthritis. Practical Radiation Oncology 2024, 15: 19-24. PMID: 39503700, DOI: 10.1016/j.prro.2024.09.003.Peer-Reviewed Original ResearchConceptsRadiation therapyAssessment of treatment responseTreatment of osteoarthritisMedically refractory diseaseNonsteroidal anti-inflammatory drugsNoninvasive treatment optionCause of painCyclooxygenase-2 inhibitorsIntra-articular corticosteroid therapyAnti-inflammatory drugsCorticosteroid therapyRefractory diseaseTreatment responseTreatment optionsClinical evidenceOlder patientsTherapyCyclooxygenase-2PatientsTraditional treatmentPhysical therapyPainTreatmentOsteoarthritisTechnical considerationsInappropriate Denials for Radiation Therapy in Medicare Advantage Plans: An Independent Review Entity and Call for Action
Pasetsky J, Kachnic L, Yu J, Horowitz D. Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans: An Independent Review Entity and Call for Action. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s127. DOI: 10.1016/j.ijrobp.2024.07.230.Peer-Reviewed Original ResearchRadiation therapyCenters for Medicare & Medicaid ServicesTraditional MedicareMA plansLife-saving cancer treatmentStatistically significant higher rateGrowing body of literatureBody of literatureMA star ratingsSignificantly higher ratesMedicare AdvantageUnfavorable decisionsHospice careStarsImprove accessCancer treatmentDenialRT servicesServicesAppealStar ratingsGrowing bodyCenters for Medicare & Medicaid Services websiteMedicare Advantage plansTherapyUpdated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C, Cheng S. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal Of Clinical Oncology 2024, 42: 1943-1952. PMID: 38507655, DOI: 10.1200/jco.23.01604.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProton beam therapyGU toxicityProstate cancerGI toxicityBenefits of proton beam therapyIntensity-modulated radiation therapy patientsPBT patientsLocalized prostate cancerTreatment-related toxicityComparison of GIStatistically significant differenceRadiation therapyBeam therapySEER-MedicareToxicity of protonProcedure codesComparative effectiveness studiesObservational studyPatientsSignificant differenceCancerMonthsComparing GIProstatePractical Considerations for the Treatment of an Adrenal Metastasis With Stereotactic Body Radiation Therapy
Yu J, Grew D, Sculley E, Hitchcock K, Kim M, Lo S. Practical Considerations for the Treatment of an Adrenal Metastasis With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2024, 14: 338-342. PMID: 38493984, DOI: 10.1016/j.prro.2024.02.003.Peer-Reviewed Original ResearchThe Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma
Lee A, Runcie K, Yu J. The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma. Kidney Cancer 2024, 8: 45-50. DOI: 10.3233/kca-230020.Peer-Reviewed Original ResearchStereotactic body radiotherapyTreatment of renal cell carcinomaRenal cell carcinomaCell carcinomaCombination of stereotactic body radiotherapyUse of stereotactic body radiotherapyNovel systemic agentsTargeted radiation therapyTreatment of RCCRadiation therapySystemic agentsCarcinomaTreatmentRCCRadiotherapyRadiation technologyIncreased useTherapyPractical Implications of the American Society for Radiation Oncology Radiation Oncology Case Rate Program Proposal for Radiation Oncologists
Yu J, Luh J, Mantz C. Practical Implications of the American Society for Radiation Oncology Radiation Oncology Case Rate Program Proposal for Radiation Oncologists. Practical Radiation Oncology 2024, 14: 196-199. PMID: 38237890, DOI: 10.1016/j.prro.2023.12.010.Peer-Reviewed Original Research
2023
National Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019
Yu J, Kinslow C, Cheng S, Ellis R, Horowitz D. National Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019. Advances In Radiation Oncology 2023, 8: 101167. PMID: 36798607, PMCID: PMC9926207, DOI: 10.1016/j.adro.2022.101167.Peer-Reviewed Original ResearchNational Cancer DatabaseIntensity modulated radiation therapyFood and Drug Administration approvalSite of diseaseImprove radiation treatmentDrug Administration approvalFood and Drug AdministrationSample of patientsRadiation therapyLinear acceleratorCancer DatabaseAdministration approvalDisease sitesRadiation treatmentComprehensive cancer centerAcademic centersCancer CenterDrug AdministrationPatientsPractice patternsTherapyCancer sitesAdapt treatmentImproved visualizationBreast
2022
Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
Gao S, Jin L, Meadows H, Shafman T, Gross C, Yu J, Aerts H, Miccio J, Stahl J, Mak R, Decker R, Kann B. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. Journal Of Thoracic Oncology 2022, 18: 339-349. PMID: 36396062, DOI: 10.1016/j.jtho.2022.11.007.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEarly-stage NSCLCBody radiation therapyDistant metastasisStage NSCLCRadiation therapyHigh-risk patient subgroupsExternal validationPatient-level riskMulti-institutional databaseTime-dependent areaGray regression modelsRandom survival forest modelDM riskSystemic therapyPatient subgroupsIndividualized riskNSCLCPatientsDM ratesDiscriminatory performanceRandom survival forestTherapyInternal validationGood calibrationA phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.
Runcie K, Dallos M, Khan S, Gray J, Marco P, Ping L, LaTourette D, Anderson C, Spina C, Yu J, Deutsch I, Sheeri S, Gutierrez A, Stein M. A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Journal Of Clinical Oncology 2022, 40: tps5115-tps5115. DOI: 10.1200/jco.2022.40.16_suppl.tps5115.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate-specific antigenTumor-associated antigensBiochemical recurrenceProstate cancerRadiation therapyTumor microenvironmentRadical prostatectomyStudy treatmentPromote anti-tumor immune responsesAntigen-specific T cell responsesBiochemical recurrence of prostate cancerBiochemically recurrent prostate cancerCastration sensitive prostate cancerPSA responseTime to PSA progressionDose of study treatmentAnti-tumor immune responseStandard first-line treatmentEvidence of metastatic diseaseMyeloid-derived suppressor cellsImmunosuppressive regulatory T cellsPeptide antigensLive-attenuated Listeria monocytogenesRecurrent prostate cancerPractice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy
Jairam V, Park HS, Yu JB, Bindra RS, Contessa JN, Jethwa KR. Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy. Advances In Radiation Oncology 2022, 7: 100949. PMID: 35521071, PMCID: PMC9065721, DOI: 10.1016/j.adro.2022.100949.Peer-Reviewed Original ResearchWhole-brain radiation therapyBrain radiation therapyRadiation oncologistsPractice patternsRadiation therapyHA-WBRTNeurocognitive declineCommon reasonHippocampal avoidance whole brain radiation therapyNational practice patternsDeleterious cognitive effectsRoutine clinical practiceNeurocognitive preservationBrain metastasesTreatment delayProvider characteristicsEffective treatmentCurrent evidencePearson χMemantineClinical practicePatientsPrior authorizationMajority of respondentsTherapy
2021
Emergency department visits for radiation cystitis among patients with a prostate cancer history
Lee V, An Y, Park HS, Yu JB, Kim SP, Jairam V. Emergency department visits for radiation cystitis among patients with a prostate cancer history. BJU International 2021, 130: 208-216. PMID: 34806813, DOI: 10.1111/bju.15650.Peer-Reviewed Original ResearchConceptsProstate cancer historyRadiation cystitisED visitsInvasive proceduresCancer historyProstate cancerRadiation therapyHigher median total chargesNationwide Emergency Department SampleEmergency department visitsEmergency Department SampleMedian total chargesPrior prostatectomyUrinary retentionBlood transfusionDepartment visitsMedian lengthEmergency departmentNational burdenSecondary diagnosisPrimary diagnosisHospital characteristicsPotential complicationsEffective modalityInvasive measuresGeographic Access to Radiation Therapy Facilities in the United States
Maroongroge S, Wallington D, Taylor P, Zhu D, Guadagnolo B, Smith B, Yu J, Ballas L. Geographic Access to Radiation Therapy Facilities in the United States. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 600-610. PMID: 34762972, DOI: 10.1016/j.ijrobp.2021.10.144.Peer-Reviewed Original ResearchConceptsRadiation therapyRT facilitiesGeographic accessOlder median ageRadiation therapy facilitiesMeasures of geographic accessU.S. populationMedian ageRT accessZIP Code Tabulation AreasState purposesLogistic regressionTherapy facilitiesHigher incomeLinear acceleratorPercentage pointsImprove accessPopulation-level measuresUnited StatesPractice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy
Jairam V, Park H, Yu J, Bindra R, Contessa J, Jethwa K. Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e569. DOI: 10.1016/j.ijrobp.2021.07.1536.Peer-Reviewed Original ResearchWhole-brain radiation therapyWhole brain radiotherapyRadiation oncologistsPractice patternsBrain radiotherapyWBRT patientsNeurocognitive declineRadiation therapyCommon reasonCurrent evidenceHippocampal-avoidance whole-brain radiotherapyN-methyl-D-aspartate receptor antagonistConventional whole brain radiotherapyBrain radiation therapyNational practice patternsDeleterious cognitive effectsRoutine clinical practiceT-testMATERIAL/METHODSStudent's t-testMost radiation oncologistsIntracranial controlNeurocognitive preservationBrain metastasesMedication costsAssociation of Heart and Lung Radiation Dose With COVID-Related Mortality
Talcott W, Peters G, Yu J, Park H. Association of Heart and Lung Radiation Dose With COVID-Related Mortality. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e424-e425. PMCID: PMC8536215, DOI: 10.1016/j.ijrobp.2021.07.1212.Peer-Reviewed Original ResearchLung radiation doseCOVID-19 infectionCOVID-related mortalityStudy cohortRadiation therapyOdds ratioRadiation dosePoor COVID-19 outcomesCOVID-19 positive patientsDosimetric parametersNon-metastatic patientsMultivariable logistic regressionConfidence intervalsNormal lung tissuesCOVID-19 outcomesLung radiation therapyCOVID-19MATERIAL/METHODSPrior radiation doseCardiovascular sequelaeEvaluable patientsHeart dosesHeart V5Lung V5Association of heartPost-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques
Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer 2021, 161: 171-179. PMID: 34607209, DOI: 10.1016/j.lungcan.2021.09.010.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyNon-small cell lung cancerCell lung cancerRadiation therapyPropensity-score matchingLA-NSCLCCardiac toxicityLung cancerAdvanced non-small cell lung cancerClinical risk factorsProportion of patientsMultivariable logistic regressionPrior treatment historyPredictors of receiptUse of IMRTConformal radiation therapyLong-term toxicityChi-squared testRadiation therapy techniquesRadiotherapy treatment techniquesUpfront surgeryElderly patientsTreatment toxicityMean ageMedicare databaseNational Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer.
Grant S, Smith B, Colbert L, Nguyen Q, Yu J, Lin S, Chen A. National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2021, 19: 1-6. PMID: 34044365, DOI: 10.6004/jnccn.2020.7688.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerMetastatic non-small cell lung cancerTreatment courseLung cancerBone metastasesSite of metastatic diseaseNational Cancer DatabaseYear of diagnosisNational Quality ForumMetastatic diseaseRadiation therapyPalliative radiationCancer DatabaseBone radiationTreatment characteristicsMultivariate analysisTreatment scheduleRate of complianceRecommended scheduleBony sitesPatientsShort courseCancerAcademic facilitiesSystematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer
Rodrigues Pessoa R, Mueller A, Boxley P, Flaig T, Piper C, Konety B, Yu J, Gershman B, Kukreja J, Kim S. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2021, 39: 786.e1-786.e8. PMID: 33846085, DOI: 10.1016/j.urolonc.2021.03.009.Peer-Reviewed Original ResearchConceptsHigh-risk non-muscle invasive bladder cancerNon-muscle invasive bladder cancerCancer specific-survivalRecurrence-free survivalInvasive bladder cancerBacillus Calmette-GuerinOverall survivalRadiation therapyBladder cancerMeta-analysisRates of recurrence-free survivalClinical trialsGoal of bladder preservationMetastatic disease rateSalvage radical cystectomyCochrane Central Register of Controlled TrialsProspective clinical trialCentral Register of Controlled TrialsTreatment of patientsRegister of Controlled TrialsSystematic reviewCochrane Central RegisterLow-quality evidenceQuality of evidenceBladder preservationCost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open 2021, 4: e2033787. PMID: 33439266, PMCID: PMC7807293, DOI: 10.1001/jamanetworkopen.2020.33787.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic hormone-sensitive prostate cancerProstate radiation therapyEconomic evaluationProstate cancerHealth-state utility estimatesIncremental cost-effectiveness ratioRadiation therapyLow-volume metastatic hormone-sensitive prostate cancerProbabilistic sensitivity analysesLow burden metastatic prostate cancerLow-volume metastatic prostate cancerCost-effectiveness ratioHormone-sensitive prostate cancerDominant treatment strategyBase case scenarioFailure-free survivalUS dollarsNet costUtility estimatesDominant strategyCost-effective treatmentHigher QALYsQALYDeprivation therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply